Contact

STAR-CRISPR™: High-efficiency, multiplexed gene editing

Capitalize on proprietary gene-editing technology that delivers multiple gene edits in a single round and reliable delivery of large genetic payloads, all in a clear IP framework.

STAR-CRISPR Designer Image

A better way to leverage guide RNA (gRNA).

STAR-CRISPR™ combines high editing efficiency and the time-savings of multiplex gene editing, with the clarity and simplicity of a  clear IP framework.

Working_Icons-3

Multiplex gene editing can dramatically reduce the year+ timeframe typically required for sequential editing, where each edit takes about four months and each iPSC-derived cell therapy requires an average of four edits.

Working_Icons 3

From a business perspective, STAR-CRISPR™ stands out with a clear and straightforward licensing framework that simplifies paperwork and speeds implementation.

Working_Icons 2-1

By increasing the efficiency of the edits themselves, STAR-CRISPR™ reduces off-target effects — meaning there’s much less chance of making unintended edits in the wrong location.

Group 35379
CRISPR Vial

CRISPR technology that delivers impressive accuracy and efficiency.

STAR-CRISPR™, the advanced technology we use in our cell line development platform and immune-cloaked cell lines, maximizes performance and safety, delivering engineered improvements over Cas9 and Cas12a in iPSC-based projects. With the distinct edge it offers in precision and speed, STAR-CRISPR™ is becoming a dominant gene-editing technology — one that’s also available for outlicensing from a single partner.

Up to 4 edits in a single round

Accelerated path to clinic thanks to multiplex editing that reduces development timelines

Off-target reductions

STAR-guides architecture improves safety with a in 40% reduction of unintended edits

Enhanced efficiency

Novel nuclear localization tags and orientation increased editing efficiency

High knock-in+ knock-out performance

90% knock-out efficiency — and knock-in efficiency that’s 2-3  times higher than other leading CRISPR-based methods when applied to iPSCs — improves product consistency and manufacturability

Bolstered IND readiness

Off-target data packs for IND submissions, with in-cell, in silico and cell-free results and top guide selections based on edit efficiency and safety

Clear IP framework

Supported by Allo Chassis™, STAR-CRISPR™, and a strong Cellistic patent estate

High-precision gene editing for high-performance programs.

STAR-CRISPR™ is built on Cas12-based editing, enabling improved target specificity through more precise target recognition, with increased design flexibility and reduced off-target activity. The resulting genomic data quality supports more reliable decision-making and accelerated development of iPSC-derived cell therapies.

Asset 4@5x
STAR-Nuclease 1

Engineered Type V Nuclease

Optimized for efficient delivery and editing

Guide RNA (gRNA) Design

Guide RNA (gRNA) Design

40% reduction in off-target compared with full-length wild-type guides

gRNA Selection Methods Icon

gRNA Selection Methods

Proprietary portfolio of tested targets and AI-based methods for off-target analysis

The direct, powerful route to gene editing iPSCs starts here.

We’re making STAR-CRISPR™ the industry’s go-to option for gene-editing in immune oncology and regenerative medicine cell therapy. That can have real benefits for your project, giving you a staged, risk-based approach to maximize performance and safety. Let’s put it work for you.